GlassScriptPhysician profile
Manaal Khan
NPI 1932861648
$1,506.71
in general payments reported to CMS, 2019-2025
28 companies · $640 in 2025
The $640 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.67 · 2022: $267 · 2023: $260 · 2024: $278 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $268.11 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $158.94 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $136.46 | 2021-2023 | |
| Amgen INC. | $78.26 | 2023-2025 | Xgeva, Evenity, Prolia |
| Abbvie INC. | $71.90 | 2024-2025 | |
| Exact Sciences Corporation | $65.78 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $62.55 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $61.44 | 2024-2025 | |
| Corcept Therapeutics | $58.49 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.27 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $49.72 | 2023 | Trelegy Ellipta |
| Amphastar Pharmaceuticals, INC. | $46.69 | 2025 | |
| Verity Pharmaceuticals INC. | $43.86 | 2025 | Tlando |
| Beta Bionics, INC. | $42.55 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Alvogen INC | $42.40 | 2024-2025 | Teriparatide |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $37.70 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.37 | 2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $22.88 | 2025 | Unithroid |
| Recordati_rare_diseases_inc. | $22.27 | 2025 | Isturisa |
| Ucb, INC. | $22.21 | 2021 | |
| Dexcom, INC. | $21.60 | 2022 | |
| Radius Health, INC. | $20.45 | 2025 | Tymlos |
| Tolmar, INC. | $18.64 | 2025 | Jatenzo |
| Acella Pharmaceuticals, LLC | $16.46 | 2025 | NP Thyroid 60 |
| Pfizer INC. | $16.04 | 2023 | |
| Inari Medical, INC. | $14.91 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sanofi-Aventis U.S. LLC | $14.52 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manaal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.